Welcome to our dedicated page for Nasus Pharma Ltd. SEC filings (Ticker: NSRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nasus Pharma Ltd. (NSRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Nasus Pharma files reports with the U.S. Securities and Exchange Commission that include current information on its clinical programs, financial condition, governance, and material agreements.
Nasus Pharma submits current reports on Form 6-K, which have covered topics such as condensed unaudited interim financial statements and management’s discussion and analysis for specified periods, leadership appointments, clinical trial milestones, and collaboration agreements. For example, Form 6-K reports have described the appointment of an Executive Vice President and Chief Financial Officer, the initiation of a Phase 2 clinical study of NS002 with first participant dosed, and expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the intranasal epinephrine program.
Filings also document capital markets events, including the registration and completion of Nasus Pharma’s initial public offering on Form F-1 and subsequent updates on the partial exercise of the underwriters’ over-allotment option. These disclosures outline the company’s stated use of proceeds, such as funding further development of its intranasal epinephrine program and general corporate purposes, and provide detail on underwriting arrangements.
As a foreign private issuer, Nasus Pharma is required to file an annual report on Form 20-F, and it supplements this with periodic Form 6-K submissions when it releases press statements or corporate presentations that are material to investors. Some 6-K filings incorporate press releases, such as the CEO’s letter to shareholders or news of regulatory clearances, directly as exhibits.
On this page, users can review Nasus Pharma’s SEC filings as they are made available through the EDGAR system. Stock Titan enhances access by pairing filings with AI-powered summaries that help explain key sections, highlight clinical and financial themes, and make lengthy documents such as financial statements and management analyses easier to understand. Investors can quickly identify filings related to clinical progress of NS002, leadership and governance changes, capital raising activities, and significant collaboration agreements.
Nasus Pharma reported positive top line Phase 2 results for NS002, its intranasal epinephrine powder for treating anaphylaxis. In 50 healthy adults, NS002 reached the critical 100 pg/mL epinephrine threshold with a median time of 1.69 minutes versus 3.42 minutes for EpiPen® (p=0.033), with higher proportions of subjects reaching this level within the first minutes.
The company highlighted approximately 50% higher epinephrine exposure in the first 10 minutes versus EpiPen®, similar peak concentrations, and consistent advantages with repeat dosing, all with no serious adverse events. Nasus plans to start a pivotal clinical study in the fourth quarter of 2026 and is hosting a conference call to discuss the data.
Nasus Pharma Ltd. reports that shareholders at a Special General Meeting held on March 5, 2026 approved all agenda items, including a full amendment and restatement of the company’s Articles of Association and an increase in its authorized share capital.
The new Articles set the registered share capital at 50,000,000 no-par value ordinary shares and clarify that all ordinary shares rank equally in rights. They also detail how the company can increase, consolidate, subdivide, or reduce share capital and handle fractional shares, forfeiture, liens, and share repurchases.
The updated Articles formalize governance structures such as a classified three‑class board of directors, procedures for shareholder proposals and director nominations, and rules for general meetings and voting. They also codify indemnification and insurance protections for officers, dividend and capitalization mechanics, and an exclusive U.S. federal forum for Securities Act claims, while keeping Israeli law as the corporate law framework.
Nasus Pharma Ltd. is changing its upcoming Special General Meeting of Shareholders to a fully virtual format because of the security situation in Israel and limits on public gatherings. Shareholders will not be able to attend in person and must join online instead.
The meeting remains scheduled for March 5, 2026 at 2:00 p.m. Israel time. Investors can access the meeting via Zoom using the published meeting link, ID, and passcode, allowing participation and voting remotely while maintaining the original timing of the meeting.
Nasus Pharma Ltd. filed a registration statement on Form F-1 to permit the resale of up to 5,390,850 Ordinary Shares, consisting of 2,695,425 Ordinary Shares held by selling shareholders and 2,695,425 Ordinary Shares issuable upon exercise of warrants. The company will not receive proceeds from resale transactions; it will receive cash only if warrants are exercised.
The prospectus discloses 11,710,808 Ordinary Shares issued and outstanding and a post‑offering adjusted total of 14,406,233 Ordinary Shares assuming full exercise of the Warrants. Recent corporate financings include a February 2026 private placement generating approximately $15.0 million in gross proceeds and interim Phase 2 results reported in January 2026 showing faster systemic absorption and higher peak epinephrine concentrations versus EpiPen; a pivotal study is planned for Q4 2026.
Nasus Pharma Ltd. submitted a report stating that it has made an updated corporate presentation available on its website in February 2026. The presentation, dated February 2026, is attached as Exhibit 99.1. The company clarifies that this material is not a prospectus or offering document and should not be treated as an offer to sell or buy any securities, or as the basis for any related contract or commitment.
Nasus Pharma closed a private placement of ordinary shares and warrants, raising aggregate gross proceeds of approximately $15.0 million before fees and expenses. The financing is intended to support development of NS002, the company’s powder-based intranasal epinephrine product for anaphylaxis, and other pipeline programs.
The company sold 2,695,425 ordinary shares and accompanying warrants to purchase up to 2,695,425 additional shares at a combined purchase price of $5.565 per share and warrant, a premium to the last NYSE American closing price before signing. The warrants have an exercise price of $6.53 per share, are immediately exercisable, and will expire on the earlier of two years from issuance and 30 trading days after Nasus announces top-line results from its NS002 pivotal study.
Nasus plans to use the net proceeds, together with existing cash and investments, to advance NS002 through pivotal clinical development and toward a New Drug Application, begin first-in-human studies for other intranasal powder products, and for working capital and general corporate purposes.
Nasus Pharma entered into a definitive agreement for a private placement with institutional and accredited investors, raising approximately $15.0 million in gross proceeds. Investors will buy 2,695,425 ordinary shares plus accompanying warrants to purchase up to 2,695,425 additional shares at a combined price of $5.565 per share and warrant.
The warrants have an exercise price of $6.53 per share, are immediately exercisable, and expire the earlier of two years from issuance or 30 trading days after announcement of top-line results from the NS002 pivotal study. Nasus plans to use the net proceeds to advance NS002 for anaphylaxis, start first-in-human studies for other pipeline products, and for working capital and general corporate purposes. The offering is expected to close on or about February 12, 2026, with placement agents receiving a 6.0% cash fee on gross proceeds and $55,000 in expense reimbursement.
Nasus Pharma Ltd. has called a Special General Meeting of shareholders for March 5, 2026, in Tel Aviv. Shareholders of record on February 9, 2026 will be entitled to vote.
On the agenda are proposals to increase authorized share capital, amend the articles of association, approve equity-based compensation for non-executive directors and the Chief Financial Officer, approve a milestone-based grant for the Chief Executive Officer, and approve a U.S. sub-plan to the company’s 2019 Incentive Option Plan.
Nasus Pharma Ltd. reported positive interim results from its Phase 2 study of NS002, an intranasal epinephrine powder being developed to treat anaphylaxis. In 25 evaluated participants, NS002 achieved a higher mean peak epinephrine plasma concentration of 655 pg/ml versus 548 pg/ml for EpiPen® and reached peak levels in 10.8 minutes compared with 15 minutes for EpiPen®.
Notably, 91% of participants given NS002 reached the 100 pg/ml epinephrine threshold at 5 minutes, versus 67% with EpiPen®, and early exposure over the first 10 minutes was higher with NS002 (AUC 55 h*pg/ml vs. 32 h*pg/ml). NS002 was well-tolerated in all 50 subjects who completed all treatment arms, with no serious adverse events and mostly mild, local effects, and its effects on blood pressure and pulse were comparable to EpiPen®. Nasus expects full Phase 2 results by the end of the first quarter of 2026 and plans to start a pivotal study in the fourth quarter of 2026.